Evidence map›Paper›PMID 40898601›Full record

ArticleActa oncologica (Stockholm, Sweden)2025

Why are not all paediatric cancer patients treated with protons? A population-based report from Sweden, 2016-2023.

Anna Asklid, Ingrid Kristensen, Ulla Martinsson, Martin Nilsson, Malin Blomstrand, Måns Agrup, Anna Flejmer, Anna-Maja Svärd, Charlotta Fröjd, Erik Almhagen and 2 more

Abstract read
In one paragraph

Article in Acta oncologica (Stockholm, Sweden), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anna AsklidDepartment of Oncology, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden. anna.asklid@ki.se.ORCID 0009-0009-3681-9345
Ingrid KristensenDepartment of Hematology, Oncology and Radiation Physics, Skane University Hospital, Lund, Sweden; Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden.ORCID 0000-0002-2742-0887
Ulla MartinssonDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.ORCID 0009-0000-2364-3875
Martin NilssonDepartment of Hematology, Oncology and Radiation Physics, Skane University Hospital, Lund, Sweden.
Malin BlomstrandDepartment of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Oncology, Institute of Clinical Sciences, University of Gothenburg, Sweden.ORCID 0009-0003-5989-0001
Måns AgrupDepartment of Oncology, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Anna FlejmerDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.ORCID 0000-0001-8425-8110
Anna-Maja SvärdDepartment of Radiation Sciences, Oncology, Umeå University, Sweden.
Charlotta FröjdDepartment of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Erik AlmhagenDepartment of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden; Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0001-8661-4019
Jacob EngellauDepartment of Hematology, Oncology and Radiation Physics, Skane University Hospital, Lund, Sweden.ORCID 0000-0003-4424-5985
Anna EmbringDepartment of Oncology, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.ORCID 0000-0002-5147-3276

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn 2015, a proton therapy (PT) facility was established in Sweden with one aim being to ensure access for all children expected to benefit from PT. Despite potential dosimetric advantages and full subsidisation, PT is not always selected. This study explores reasons for choosing alternative radiotherapy (RT) modalities in a paediatric population. MATERIAL AND

methodsRT courses delivered to patients ≤ 18 years during 2016-2023 were identified from a national registry. Medical records were retrospectively reviewed to identify reasons for not selecting PT.

resultsOnly 34% (n = 275) of all courses identified were delivered with PT. Of the remaining 66% (n = 544), 90% were photon RT, 9% combined PT and photon RT, and 1% electron RT. Among photon RT courses, 97% were delivered with conventional external beam radiotherapy (EBRT), 2% with stereotactic radiotherapy (SRT), and 1% with brachytherapy. The most common reason for choosing photons was non-curative intent (35%), followed by equal or superior expected outcome compared to PT (23%), total body irradiation (TBI) (15%), and uncertainties due to air, organ motion, or metal in field (15%). Dosimetric comparison led to the selection of a favourable or equal photon plan in 8%. Logistical, social, and technical reasons constituted 4%.

conclusionWhile PT can reduce radiation exposure to healthy tissues, particularly important in children, clinical, logistical, and technical factors often necessitate alternative RT modalities. This study highlights the importance of individualised RT planning and multidisciplinary collaboration to balance medical, technical, and practical considerations to ensure optimal treatment approach in every child.

Indexed as

NeoplasmsProton TherapyAdolescentChildChild, PreschoolFemaleHumansInfantMaleRadiotherapy DosageRadiotherapy Planning, Computer-AssistedRegistriesRetrospective StudiesSweden

Identifiers

PMID40898601
PMCPMC12416337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.